SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: 777 Captain who wrote (19175)3/2/1999 2:01:00 PM
From: Andreas Samson  Read Replies (2) of 23519
 
From Cruttenden Roth 9/1/98:

'...The confounding issues that cause us to believe the company will have more difficulty partnering are:

- As time elapses, we believe MUSE, currently without a distribution arm in the US, will lose more value as prescriptions decline and the proposition of regaining market share by an acquiring company becomes more difficult.

-More costly to a big pharmaceutical company to re-launch the product rather than assume reigns of the company.

-The uncertainty of the potential impact of Viagra's launch in Europe makes projecting sales very difficult at best and compromises the company's negotiating position.

-as the company prepares to sell itself, we believe the value diminishes over the next 3-6 months...'

Then, on 10/18: 'We believe the company's long-term viability is at risk unless the company secures a marketing partner for MUSE in the near future. Without a marketing presence, the value of MUSE decreases daily as it becomes more difficult to re-launch the product.'
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News